Skip to main content

Table 5 Prevalence of Asthma Symptoms and Other Allergic Conditions According to Region and Active smoking

From: Prevalence of asthma and other allergic conditions in adults in Khuzestan, southwest Iran, 2018

Asthma symptoms and other allergic conditions

Region

Active smoking

Urban

Rural

P-value¥

Yes

NO

P-value¥

Yes

%a (95% CI)

Yes

%a(95% CI)

Yes

%a(95% CI)

Yes

%a(95% CI)

Asthma-like symptoms

968

19.7 (16.3–23.2)

91

13.7(7.4–20.0)

0.133

201

23.1(18.6–27.6)

839

18.0(14.8–21.2)

0.010*

Wheezing

670

13.7 (11.2–16.3)

58

8.9(4.3–13.5)

0.110

150

17.3(13.5–21.1)

560

12.0(9.7–14.4)

0.002*

Wheezing with shortness of breath

625

13.0 (10.8–15.2)

49

7.1(4.2–10.0)

0.005*

121

14.1(11.1-17.2)

538

11.7(9.6–13.7)

0.107

Wheezing in the absence of a cold

608

12.8 (10.5–15.1)

48

7.1(4.0–10.2)

0.012*

117

13.8(10.7-17.0)

527

11.5(9.4–13.7)

0.132

Waking with tightness in the chest

630

12.8 (10.5–15.1)

60

8.9(5.3–12.5)

0.102

125

14.4(11.2–17.5)

554

11.8(9.6–14.0)

0.106

Woken by an attack of breathlessness

528

10.7 (8.8–12.6)

52

7.6(4.6–10.7)

0.129

104

12.0(9.3–14.6)

466

9.9(8.1–11.7)

0.115

Woken by attack of cough

706

14.2 (11.8–16.7)

62

9.1(5.6–12.6)

0.033*

143

16.4(13.1-19.7)

613

12.9(10.6–15.3)

0.033*

Current asthma

447

9.1 (7.4–10.8)

31

4.5(2.3–6.8)

0.008*

103

11.9(9.1-14.7)

367

7.8(6.1–9.4)

0.004*

Asthma attack

385

7.8 (6.2–9.4)

25

3.5(1.6–5.5)

0.006*

84

9.7(7.2-12.2)

321

6.8(5.2–8.4)

0.030*

Medications for asthma

387

7.9 (6.4–9.4)

30

4.4(2.2–6.5)

0.026*

85

9.8(7.4-12.3)

326

6.9(5.4–8.4)

0.026*

Physician-confirmed asthma

329

6.7 (5.5–7.9)

30

4.5(1.9–7.2)

0.204

72

8.3(6.1–10.6)

280

6.0(4.8–7.1)

0.031*

Allergic Rhinitis

1323

26.7 (24.5–29.0)

190

27.1(21.4–32.7)

0.907

286

32.8(29.0–36.7)

1209

25.5(23.3–27.7)

< 0.001*

Airway hyperresponsiveness

1913

38.3 (34.5–42.2)

277

40.8(30.9–50.7)

0.646

393

44.6(39.5–49.7)

1767

37.3(33.5–41.1)

0.006*

Eczema

510

10.3 (8.7–12.0)

95

13.5(9.8–17.2)

0.099

121

13.7(10.9–16.4)

472

10.0(8.5–11.6)

0.005*

  1. a: Prevalence estimates were weighted using normalized cross-sectional weights
  2. ¥ χ2 test
  3. *P < 0.05